Name of journal: *World Journal of Stem Cells*

ESPS Manuscript NO: 12878

Columns: MINIREVIEW

**How do resident stem cells repair the damaged myocardium?**

Running Title: **Hayashi E *et al.* How do stem cells repair myocardium?**

Emiko Hayashi, Toru Hosoda

Medical Science Division, Tokai University Institute of Innovative Science and Technology, Kanagawa 259-1193, Japan

**Author contributions:** Hayashi E drafted the text, and Hosoda T finalized the paper.

**Supported by** the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C) 25461118

**Correspondence to:** Toru Hosoda, M.D., Ph.D., Medical Science Division, Tokai University Institute of Innovative Science and Technology, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. hosoda@tokai-u.jp

**Telephone:** Tel: +81-463-93-1121 (Ext. 2784) **Fax:** +81-463-95-3522

**Abstract**

It has been a decade since the monumental discovery of resident stem cells in the mammalian heart, and the following studies witnessed the continuous turnover of cardiomyocytes and vascular cells, maintaining the homeostasis of the organ. Recently, the autologous administration of c-kit-positive cardiac stem cells in patients with ischemic heart failure has led to an incredible outcome; the left ventricular ejection fraction of the cell-treated group improved from 30% at the baseline to 38% after one year and to 42% after two years of cell injection. The potential underlying mechanisms, before and after cell infusion, are explored and discussed in this article. Some of them are related to the intrinsic property of the resident stem cells, such as direct differentiation, paracrine action, and immunomodulatory function, whereas others involve environmental factors, leading to cellular reverse remodeling and to the natural selection of “juvenile” cells. It has now been demonstrated that cardiac stem cells for therapeutic purposes can be prepared from tiny biopsied specimens of the failing heart as well as from frozen tissues, which may remarkably expand the repertoire of the strategy against various cardiovascular disorders, including non-ischemic cardiomyopathy and congenital heart diseases. Further translational investigations are needed to explore these possibilities.

**Keywords**

Regeneration, Heart failure, Cell therapy, c-kit, Cardiac stem cells, Cellular reverse remodeling, Mircrine

**Core Tip**

The autologous transplantation of cardiac stem cells appeared to be safe and surprisingly effective for a small group of patients with chronic ischemic cardiomyopathy. Their specific feature as resident stem cells, the interaction with the surrounding tissue, and the natural selection during the cell culture process potentially contributed together to the outstanding consequences.

**Introduction**

The advancement of emergency medicine enabled us to rescue many patients with acute myocardial infarction, but they may eventually develop and suffer from chronic heart failure later in life. Accordingly, the demand of alternative approaches to chronic ventricular dysfunction is increasing dramatically. For decades, the mammalian heart was recognized as a postmitotic terminally differentiated organ, in which the number of cardiomyocytes was believed to be constant throughout the life span of organisms. Early this century, however, the existence of resident cardiac stem cells (CSCs) was unveiled[1], questioning the validity of the long-lasting theory. The uninterrupted renewal of human myocardium in physiological and pathological circumstances has been depicted[2], promoting our understanding of the self-renewing characteristic of the heart. This paradigm shift not only shook the biological dogma but revealed the possibility of an unprecedented therapeutic strategy for devastating diseases.

**CLINICAL application of cardiac stem cells**

By virtue of the explorations following the discovery of resident CSCs, the human heart has been characterized by the persistent renewal of its components, muscles and vessels. Moreover, by utilizing animal models, c-kit-positive CSCs are shown to regenerate the diseased myocardium of ischemic and non-ischemic origins[3-5]. Subsequently, in 2009 the first clinical use of autologous CSCs began; in this SCIPIO trial, the subjects with severe ischemic heart failure received an elective coronary artery bypass graft surgery, during which a tiny piece of the right atrial appendage was resected as the source of stem cells. Four months after the operation, only those with the left ventricular ejection fraction (LVEF) worse than 40% were included in the trial and randomly assigned to the control or cell-treated groups. While the cardiac function did not change in the control group, the LVEF dramatically improved in the treated patients, from 30% at the baseline to 38% after one year and to 42% after two years of cell administration[6,7]. The infarct size evaluated by an MRI remarkably reduced following the cell therapy, and the symptom improved as well. It should be noted that the major adverse cardiac event rate was unchanged with or without this therapeutic intervention[8].

**direct differentiation VS. Paracrine ACTION**

A single intracoronary injection of 1,000,000 CSCs, as described above, appeared to be safe and effective for 2 years or longer. How does this work? There are accumulated evidences suggesting that most cell types applied for heart failure, including skeletal myoblasts, bone marrow-derived cells, and cardiosphere-derived cells[9,10], function through paracrine mechanisms[11-13]. In this regard, CSCs are found to work through the sequential processes of engraftment, proliferation, and direct differentiation into various cardiac cell types[14], in addition to the paracrine action[15,16]. Actually, a recent study showed that the injection of 200 million human mesenchymal stem/stromal cells (MSCs) and that of one million c-kit-positive CSCs into a two-week-old infarcted myocardium were similarly effective, revealing the great regenerative potential of resident stem cells[17]. Interestingly, the combined usage of these distinct cells resulted in a synergistic effect, formulating an attractive regimen for myocardial infarction.

**regulation of immune response**

The environment of the host tissue is not always favorable for the transplanted cells to engraft, especially when allogeneic ones are used. Historically, MSCs were found to be immunoprivileged, due to their lack of major histocompatibility complex class II antigen. In fact, the endomyocardial injections of autologous and allogeneic bone marrow MSCs were similarly effective as a treatment for ischemic heart failure patients[18]. More recently, Di Trapani M *et al.* have demonstrated that certain stem cells of various sources, including CSCs, are able to regulate the immune response of the recipient[19]. Such properties may have a role *in vivo* in enhancing their regenerative ability, especially in inflammatory circumstances. These reports would support the enthusiasm for the “off-the-shelf” usage of allogeneic CSCs. The obvious advantages include minimizing the lot-to-lot variation of cell therapy and its applicability to the acute phase of the disease. Following the differentiation of engrafted CSCs *in vivo*, however, the immune system of the host may reject them, just like in the case with rat MSCs[20]. Although this particular study was carried out with rodents, stem cells of any given species would become immunogenic upon the acquisition of myogenic phenotypes. In the setting of allogeneic transplantation, therefore, the long-term benefit depends essentially on the paracrine action of the administered cells. Further evaluations would be needed to compare the advantages and disadvantages of respective therapeutic strategies.

**reverse remodeling at cellular level**

As stated above, while the administered cells may affect the circumstance, the microenvironment within the host would also influence the destiny of the exogenous cells. Based on the studies using immunosuppressed animals, human CSCs can create more cardiomyocytes than the lost myocytes of the recipient, within one month after injection[21]. Assuming a comparable growth behavior of the autologous CSCs, it might be unlikely that these cells divided continuously and frequently for more than 2 years. Instead, it would be reasonable to speculate that each differentiated progeny gradually matured to improve the global function of the organ. Lately, it was shown that microRNAs (miRs) can traverse gap junctions and influence the fate of the cells receiving these miRs. Specifically, miR-499, which is abundant in cardiomyocytes and essentially absent in CSCs, can be transferred from myocytes to resident stem cells *via* gap junction channels, resulting in the enhanced differentiation of the primitive cells toward myocytic lineage[22]. Therefore, it can be presumed that the presence or absence of matured myocytes in a microenvironment determines the destiny of stem cells *in situ*. Actually, this theory is consistent with the previous observation in which CSCs engrafted in remote myocardium, full of surviving mature cells, progressively differentiate to become indistinguishable from its surrounding myocytes within five weeks[23]. On the contrary, at the infarcted/regenerated area, cardiomyocytes derived from injected CSCs tend to hold fetal/neonatal characteristics for the same period of time. Once committed to the myocytic lineage, CSCs themselves start to express miR-499, and the quantity increases as the differentiation process advances, which in turn may have an influence on neighboring immature cells through the mircrine mechanism. This cascade of progressive maturation may be called “cellular reverse remodeling”.

**CONSEQUENCE of cell expansion**

Another essential factor can be pointed out in the cell preparation procedure. The necessity of CSC cultivation prior to injection basically excludes the autologous implantation at the acute stage, and this is generally considered to be a major drawback of somatic stem cell treatments. This inevitable culturing step, however, may hold an advantageous aspect as well. Because rapidly multiplying “juvenile” cells grow faster than “senile” ones on the dish, this maneuver practically functions as a natural selection process. Conversely, when cells harvested from a body are used directly to treat an acute illness, the cell population may be heterogeneous by nature within the patients as well as among the preparations for various patients. Needless to say, it is unlikely that a longer culturing period gives a better outcome; there should be a certain threshold. Accordingly, CSCs should be characterized better, in order to pick the right timing and method for the cell preparation step.

**PERSPECTIVE**

The clinical applications of resident CSCs began only five years ago. Due to the limited number of subjects and the relatively short observational period, we still do not yet know whether this therapy will improve hard endpoints such as the survival of patients. Also, the treatment was mainly applied to patients who required cardiac surgery. However, a recent research indicated that tiny pieces of the failing heart, ~5 mg in weight, are sufficient for CSC preparation[24]. Moreover, our group has lately succeeded in culturing CSCs from small surgical specimens kept frozen for longer than a year; the isolated cells possessed properties comparable to that of those derived from fresh tissues (unpublished observation). This is clinically relevant and important, in light of the potential repetitive treatment of a single patient and/or applications to adult congenital heart diseases. We have to investigate further to see whether such repeated CSC injections and its usage for pediatric patients are safe and effective as expected. This endeavor will be able to salvage a large number of patients who do not have adequate therapeutic options at the present time.

**References**

1. **Beltrami AP**, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 2003; **114**: 763-776 [PMID: 14505575 DOI: 10.1016/S0092-8674(03)00687-1]
2. **Kajstura J**, Gurusamy N, Ogórek B, Goichberg P, Clavo-Rondon C, Hosoda T, D’Amario D, Bardelli S, Beltrami AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anversa P. Myocyte turnover in the aging human heart. *Circ Res* 2010; **107**: 1374-1386 [PMID: 21088285 DOI: 10.1161/CIRCRESAHA.110.231498]
3. **Bearzi C**, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins RW, Lecapitaine N, Cascapera S, Beltrami AP, D’Alessandro DA, Zias E, Quaini F, Urbanek K, Michler RE, Bolli R, Kajstura J, Leri A, Anversa P. Human cardiac stem cells. *Proc Natl Acad Sci USA* 2007; **104**: 14068-14073 [PMID: 17709737 PMCID: PMC1955818 DOI: 10.1073/pnas.0706760104]
4. **De Angelis A**, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, Urbanek K, Kajstura J, Leri A, Rossi F, Anversa P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. *Circulation* 2010; **121**: 276-292 [PMID: 20038740 PMCID: PMC2810713 DOI: 10.1161/CIRCULATIONAHA.109.895771]
5. **Hosoda T**. C-kit-positive cardiac stem cells and myocardial regeneration. *Am J Cardiovasc Dis* 2012; **2**: 58-67 [PMID: 22254215 PMCID: PMC3257153]
6. **Bolli R**, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomized phase 1 trial. *Lancet* 2011; **378**: 1847-1857 [PMID: 22088800 PMCID: PMC3614010 DOI: 10.1016/S0140-6736(11)61590-0]
7. **Bolli R**, Chugh A, D’Amario D, Loughran JH, Stoddard MF, Ikram S, Wagner SG, Beache GM, Leri A, Hosoda T, Goichberg P, Fiorini C, Solankhi N, Fahsah I, Elmore JB, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Effect of cardiac stem cells in patients with ischemic cardiomyopathy: interim results of the SCIPIO trial up to 2 years after therapy [abstract]. *Circulation* 2012; **126**: 2784 [DOI: 10.1161/CIR.0b013e318278c90d]
8. **Chugh AR**, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. *Circulation* 2012; **126**: S54-S64 [PMID: 22965994 PMCID: PMC3448934 DOI: 10.1161/CIRCULATIONAHA.112.092627]
9. **Smith RR**, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marbán E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. *Circulation* 2007; **115**: 896-908 [PMID: 17283259 DOI: 10.1161/CIRCULATIONAHA.106.655209]
10. **Makkar RR**, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomized phase 1 trial. *Lancet* 2012; **379**: 895-904 [PMID: 22336189 DOI: 10.1016/S0140-6736(12)60195-0]
11. **Chimenti I**, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marbán E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circ Res* 2010; **106**: 971-980 [PMID: 20110532 DOI: 10.1161/CIRCRESAHA.109.210682]
12. **Hayashi E**, Hosoda T. Therapeutic application of cardiac stem cells and other cell types. *Biomed Res Int* 2013; **2013**: 736815 [PMID: 23878816 PMCID: PMC3708396 DOI: 10.1155/2013/736815]
13. **Maxeiner H**, Mufti S, Krehbiehl N, Dülfer F, Helmig S, Schneider J, Böning A, Matejec R, Weigand MA, Schlüter KD, Wenzel S. Interleukin-6 Contributes to the Paracrine Effects of Cardiospheres Cultured from Human, Murine and Rat Hearts. *J Cell Physiol* 2014; In press [PMID: 24623002 DOI: 10.1002/jcp.24613]
14. **Hosoda T**, Rota M, Kajstura J, Leri A, Anversa P. Role of stem cells in cardiovascular biology. *J Thromb Haemost* 2011; **9 Suppl 1**: 151-161 [PMID: 21781250 PMCID: PMC4071762 DOI: 10.1111/j.1538-7836.2011.04363.x]
15. **Tang XL**, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, Li C, Chen N, Peng Y, Dawn B, Hunt G, Leri A, Kajstura J, Tiwari S, Shirk G, Anversa P, Bolli R. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation* 2010; **121**: 293-305 [PMID: 20048209 PMCID: PMC2814341 DOI: 10.1161/CIRCULATIONAHA.109.871905]
16. **Kawaguchi N**, Smith AJ, Waring CD, Hasan MK, Miyamoto S, Matsuoka R, Ellison GM. c-kitpos GATA-4 high rat cardiac stem cells foster adult cardiomyocyte survival through IGF-1 paracrine signalling. *PLoS One* 2010; **5**: e14297 [PMID: 21179204 PMCID: PMC3001457 DOI: 10.1371/journal.pone.0014297]
17. **Williams AR**, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. *Circulation* 2013; **127**: 213-223 [PMID: 23224061 PMCID: PMC3579523 DOI: 10.1161/CIRCULATIONAHA.112.131110]
18. **Hare JM**, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA* 2012; **308**: 2369-2379 [PMID: 23117550 DOI: 10.1001/jama.2012.25321]
19. **Di Trapani M**, Bassi G, Ricciardi M, Fontana E, Bifari F, Pacelli L, Giacomello L, Pozzobon M, Féron F, De Coppi P, Anversa P, Fumagalli G, Decimo I, Menard C, Tarte K, Krampera M. Comparative study of immune regulatory properties of stem cells derived from different tissues. *Stem Cells Dev* 2013; **22**: 2990-3002 [PMID: 23819720 PMCID: PMC3840473 DOI: 10.1089/scd.2013.0204]
20. **Huang XP**, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD, Li RK. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. *Circulation* 2010; **122**: 2419-2429 [PMID: 21098445 DOI: 10.1161/CIRCULATIONAHA.110.955971]
21. **D'Amario D**, Cabral-Da-Silva MC, Zheng H, Fiorini C, Goichberg P, Steadman E, Ferreira-Martins J, Sanada F, Piccoli M, Cappetta D, D'Alessandro DA, Michler RE, Hosoda T, Anastasia L, Rota M, Leri A, Anversa P, Kajstura J. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. *Circ Res* 2011; **108**: 1467-1481 [PMID: 21546606 PMCID: PMC3299060 DOI: 10.1161/CIRCRESAHA.111.240648]
22. **Hosoda T**, Zheng H, Cabral-da-Silva M, Sanada F, Ide-Iwata N, Ogórek B, Ferreira-Martins J, Arranto C, D'Amario D, del Monte F, Urbanek K, D'Alessandro DA, Michler RE, Anversa P, Rota M, Kajstura J, Leri A. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. *Circulation* 2011; **123**: 1287-1296 [PMID: 21403094 PMCID: PMC3066266 DOI: 10.1161/CIRCULATIONAHA.110.982918]
23. **Dawn B**, Stein AB, Urbanek K, Rota M, Whang B, Rastaldo R, Torella D, Tang XL, Rezazadeh A, Kajstura J, Leri A, Hunt G, Varma J, Prabhu SD, Anversa P, Bolli R. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. *Proc Natl Acad Sci USA* 2005; **102**: 3766-3771 [PMID: 15734798 PMCID: PMC553298 DOI: 10.1073/pnas.0405957102]
24. **D'Amario D**, Fiorini C, Campbell PM, Goichberg P, Sanada F, Zheng H, Hosoda T, Rota M, Connell JM, Gallegos RP, Welt FG, Givertz MM, Mitchell RN, Leri A, Kajstura J, Pfeffer MA, Anversa P. Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. *Circ Res* 2011; **108**: 857-861 [PMID: 21330601 PMCID: PMC3074470 DOI: 10.1161/CIRCRESAHA.111.241380]